Search 

Our team at the Maryland Department of Commerce assists companies to establish operations and partnerships in one of the leading ecosystems for the life science industry in the United States.
- As one of the nation’s largest and fastest growing biotechnology clusters, Maryland is #1 in Ph.D. concentration in biological fields, employed doctoral scientists, and was recognized last year at the 4th best biotechnology cluster in the nation by Genetic Engineering and Biotechnology News.
- We have facilitated access to 74 Federal laboratories, including the National Institutes of Health, the National Institute for Standards and Technology, the Food and Drug Administration, and the Walter Reed Army Institute of Research.
- We can reach 80% of the U.S. pharmaceutical industry and four nearby international airports to enable efficient travel.
- Maryland’s Cost of Doing Business Index is 16%, 12%, and 10% lower than in Boston, New Jersey, and California, respectively, according to Moody’s Analytics Regional Financial Review. In our industry, that translates to a lower cost of operations and wet lab space.
- The cost of living in Maryland can be up to one-and-a-half times lower than in the metropolitan areas of New York, Boston, and San Francisco, according to the Council for Community and Economic Research.

MaveriX Oncology is exploiting cancer and immune cell metabolism to discover and develop new targeted therapeutics that challenge the limitations of current chemotherapy and immunotherapy. The MaveriX technology approach is a multi-target, multi-asset small-molecule platform with potential first and best-in-class therapeutics designed for monotherapy and combination chemotherapy and immunotherapy. Our experienced team of pharma executives is developing a proprietary pipeline of drug candidates with the goal of bring new and improved treatments to patients that suffer from cancer. Our lead program MVX5005 (E037) is well tolerated and exhibits broad, single- agent anti-tumor activity in preclinical mouse models of cancer. The unique mechanism-of-action targets cancer cells directly, induces immunogenic cell death while eradicating immune suppressive cells within the tumor microenvironment. E037 is currently completing IND-enabling studies targeting clinical entry Q3 2021. The company is currently raising capital and seeking strategic partnership opportunities to support clinical development to POC with differentiated platform expansion.

MaveriX Oncology, Inc., is a globally-orientated biotechnology company focused on the discovery and development of novel targeted small-molecule chemo-immunotherapies. The MaveriX technology approach exploits oncogenic and immunogenic targets that are over-expressed to a high frequency in the majority of solid tumors and hematological malignancies. This is a multi-target, multi-asset small-molecule platform technology with potential first and best-in-class therapeutics designed primarily for monotherapy activity in the clinic but with a robust mechanistic rational for combination chemotherapy and immunotherapy. Our experienced team of pharma executives is developing a proprietary pipeline of drug candidates with the goal of bringing new and improved treatments to patients suffering from cancer. Our lead program MVX5005 (E037) is well tolerated with broad single agent anti-tumor activity, can overcome key resistance mechanisms in cancer, and challenge the limitations of current chemotherapy and immunotherapy approaches. MVX5005 is currently completing formal IND-enabling studies, targeting clinical entry beginning Q3 2021 (phase 1a dose escalation with disease-specific expansion cohorts for monotherapy plus phase 1b combination chemotherapy and immunotherapy).

MEDGENE is a T cell therapy biotech start-up (late pre-clinical stage) based in Maryland, USA.
- Focused on developing PD1+ peripheral blood-derived, tumor-reactive CD8+ T cell (PBTL) therapies as a platform for the treatment of solid tumors that are rare, orphan, and have critical (high) unmet need
- PBTL is a simpler, smarter version of TIL
- PBTL is a process to select highly tumor-reactive T cells from a patient's peripheral blood based on the expression of two specific T cell surface markers: PD-1 and/or TIM-3
- After selection, expanded to large quantities, it gets re-infused into the patient via the ACT regimen
- PBTL technology has been patented (issued) already in the US, China, the EU, Japan, Australia
- MEDGENE has robust Clinical Development Pipelines (currently, 9 as monotherapy way)
- Looking for funding for entering Phase I/2 in three pipelines in the US
- Looking for partnering for the Asian market (China, Japan, South Korea)

A CAP, CLIA And AABB certified clinical lab specialized in genetic and molecular diagnosis

MedSci Healthcare was established in 2002 with the creation of Bioon.com, with headquarters in Shanghai and internationally in the U.S. We are committed to be the bridge between China and the U.S. healthcare. This is done by connecting Chinese healthcare professionals (HCPs) with U.S. resources and vice versa.
The company has done projects with major companies such as: Pfizer, Harvard Medical School, AstraZeneca, GSK, Abbott, Johnson & Johnson, Takeda, Novartis, Medtronic and many more. We have also worked with organizations such as the China Cardiovascular Association (CCA), Chinese Medical Doctor Association (CMDA) and more.
MedSci is a digital academic platform, scientific publishing support and multichannel marketing (MCM) organization. We use the term Academic Promotion Organization (APO). We use scientific writers, doctors & researcher scientists and commercialization experts to develop customized strategy & implementation to reach each organization’s goals.

Medical Device Company

MedWorld Advisors is an international M&A Services Firm. We represent medical technology companies from the US, EU and Israel that want to enter the China market. We facilitate licensing, commercialization and acquisition deals between our clients and larger companies / investors in China. We are based in Boston in the U.S. We also have an operation in Hong Kong to help facilitate deals, as helpful.

Biopharmaceutical

Life Sciences venture capital fund with three funds under management.

MID Labs has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, we have been instrumental in revolutionizing the ophthalmic field through our products.

MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.